RT Journal Article SR Electronic T1 Gut colonization of Enterococcus species is associated with COVID-19 disease in Uganda JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2024.09.28.24314457 DO 10.1101/2024.09.28.24314457 A1 Agudelo, Carolina A1 Kateete, David Patrick A1 Nasinghe, Emmanuel A1 Kamulegeya, Rogers A1 Lubega, Christopher A1 Mbabazi, Monica M A1 Baker, Noah A1 Lin, Kathryn A1 Liu, Chang C. A1 Kasambula, Arthur Shem A1 Kigozi, Edgar A1 Komakech, Kevin A1 Mukisa, John A1 Mulumba, Kassim A1 Mwachan, Patricia A1 Nakalanda, Brenda Sharon A1 Nalubega, Gloria Patricia A1 Nsubuga, Julius A1 Sitenda, Diana A1 Ssenfuka, Henry A1 Cirolia, Giana A1 Gustafson, Jeshua T. A1 Wang, Ruohong A1 Nsubuga, Moses Luutu A1 Yiga, Fahim A1 Stanley, Sarah A. A1 Bagaya, Bernard Ssentalo A1 Elliott, Alison A1 Joloba, Moses A1 Wolf, Ashley R. YR 2024 UL http://medrxiv.org/content/early/2024/09/30/2024.09.28.24314457.abstract AB Background Infection with the COVID-19-causing pathogen SARS-CoV-2 is associated with disruption in the human gut microbiome. The gut microbiome enables protection against diverse pathogens and exhibits dysbiosis during infectious and autoimmune disease. Studies based in the United States and China have found that severe COVID-19 cases have altered gut microbiome composition when compared to mild COVID-19 cases. We present the first study to investigate the gut microbiome composition of COVID-19 cases in a population from Sub-Saharan Africa. Given the impact of geography and cultural traditions on microbiome composition, it is important to investigate the microbiome globally and not draw broad conclusions from homogenous populations.Results We used stool samples in a Ugandan biobank collected from COVID-19 cases during 2020-2022. We profiled the gut microbiomes of 114 symptomatic individuals who tested positive for SARS-CoV-2 along with 76 household contacts who did not present any symptoms of COVID-19. The inclusion of healthy controls enables us to generate hypotheses about bacterial strains potentially related to susceptibility to COVID-19 disease, which is highly heterogeneous. Comparison of the COVID-19 patients and their household contacts revealed decreased alpha diversity and blooms of Enterococcus and Eggerthella in COVID-19 cases.Conclusions Our study finds that the microbiome of COVID-19 individuals is more likely to be disrupted, as indicated by decreased diversity and increased pathobiont levels. This is either a consequence of the disease or may indicate that certain microbiome states increase susceptibility to COVID-19 disease. Our findings enable comparison with cohorts previously published in the Global North, as well as support new hypotheses about the interaction between the gut microbiome and SARS-CoV-2 infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was funded by the Alliance for Global Health and Science, Fast Grants (part of Emergent Ventures at George Mason University) awarded to S.A.S., the Science for Africa Foundation (reference # GCA/SARSCov2-2-20-006 to AE & DPK), the Office of the President, PRESIDE (grant number OP-STLPRESIDE PATHOGEN-2021/2022), Project COVBANK grant, and NIH R35 GM147512 to A.R.W. C.A. is funded by an NSF Graduate Research Fellowship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Research & Ethics Committee of Mulago National Referral Hospital and the Uganda National Council for Science and Technology gave ethical approval to this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesSequencing reads have been submitted to the NCBI Short Read Archive under Bioproject PRJNA1131762. A link to the data is available by request.